616452 compound,
E 616452,
E-616452,
E616452,
RepSox,
RepSox,
446859-33-2,
ALK5 Inhibitor II,
ALK5 Inhibitor,
SJN 2511,
2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine,
E-616452,
GW786460X,
CHEMBL185238,
TGF-beta RI Kinase Inhibitor II,
C17H13N5,
2-(3-(6-Methylpyridine-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine,
2-[3-(6-Methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5-naphthyridine,
Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor II,
2-(5-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine,
2-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-1,5-naphthyridine,
2-[5-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-1,5-naphthyridine,
1vjy,
Alk 5 Inhibitor II,
PubChem24163,
AC1L9MO3,
GW786460X (Repsox),
MLS006011123,
SCHEMBL144632,
SCHEMBL16969100,
CTK8E7448,
RepSox, >=98% (HPLC),
AOB1483,
DTXSID80332295,
LBPKYPYHDKKRFS-UHFFFAOYSA-N,
HMS2043P13,
HMS3261N03,
HMS3653M19,
BCP04103,
SJN-2511,
Tox21_500541,
1,5-Naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-,
ABP000974,
BDBM50151347,
IN1052,
MFCD09037561,
s7223,
ZINC16052804,
AKOS016009677,
BCP9000274,
CCG-221845,
CS-1321,
RL03695,
NCGC00242054-01,
NCGC00242054-02,
NCGC00242054-03,
NCGC00261226-01,
4CA-1165,
AC-28395,
AJ-68089,
AJ-68090,
AK-35200,
AS-16653,
DA-42419,
EN002636,
HY-13012,
Repsox pound ALK5 Inhibitor II pound(c),
SC-96580,
SMR004702903,
BCP0726000102,
AB0007897,
AX8160241,
FT-0759246,
SW212662-2,
X5942,
J3.496.867E,
W-5394,
AB01092249-01,
GW786460X (616452),
E 616452,
J-507645,
2-[3-(6-Methyl-2-pyridyl)-1H-pyrazole-4-yl]-1,5-naphthyridine,
2-[3-(6-Methyl-pyridin-2-yl)-1H-pyrazol-4-yl]-[1,5]naphthyridine,
E-616452; 2-[3-(6-Methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5-naphthyridine,
cc-232,
CID449054,
A3754,
A11762,
2-[3-(6-methylpyridin-2-yl)-2H-pyrazol-4-yl]-1,5-naphthyridine,
2-[5-(6-METHYLPYRIDIN-2-YL)-2,3-DIHYDRO-1H-PYRAZOL-4-YL]-1,5-NAPHTHYRIDINE,